

ASX: RSH
OTCQB: RSHUF



Respiri – Building on a Foundation of Strategic Firsts

An integrated, scalable and **proven growth engine** to deliver remote patient monitoring (RPM) solutions to the US healthcare market

Marjan Mikel (CEO)

August 2023

Forward looking



Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release.

The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



Public market overview

Share price	A\$0.032
52-week range	A\$0.027 to A\$0.075
Market capitalisation	A\$31.16m
Ordinary Shares on issue	974m
Options	283m (circa average price exercisable at A\$0.15)



Board of Directors

Nicholas Smedley	Executive Chairman
Marjan Mikel	Managing Director
Brad Snow (USA Based)	Non-Exec Director
Brian Leedman	Non-Exec Director



Major shareholders

Netwealth Investments Ltd (Wrap Services)	4.77%
Netwealth Investments Ltd (Super Services)	3.82%
BNP Paribas Nominees Pty Ltd	3.79%
Citicorp Nominees Pty Limited	2.15%
Mallamanda Pty Ltd (Mallamanda A/C)	1.85%
Mr Peter Karl Braun	1.85%
Top 20 Shareholders	31.85%
Top 100 Shareholders	61.93%

Respiri - A Unique Company of USA firsts

1998



PULMOTRACK/ WHOLTER

Our first FDA-approved electronic wheeze monitoring device.

2010



WHEEZOMETER

Respiri's first portable wheeze monitor.

2017



AIRSONEA

The next device iteration had a basic app.

2021



wheezo® FDA CLEARED

A breath sensor that works with the app to record and detect wheeze.

Respiri Delivers Strategic Firsts

The 1st and only Australian company to:

FIRST

to **gain FDA clearance** for its unique WheezeRate Detector, - wheezo®



FIRST

to **deliver end-to-end RPM services** to US health providers with the **Access** acquisition



FIRST

to **be successfully reimbursed for RPM** by Centers of Medicare and Medicaid (**CMS**) in the **USA**.



The Expensive Healthcare Problem

- + Traditional model of care is reactive and failing patients
- + Cycle of re-admission rates continue to put strain on US Health System
- + Hospital Readmissions targets have been legislated. Fines have been issued by CMS to Hospitals for failing to meet these targets



~50m Americans (COPD/Asthma)¹⁻³

~17%^{4,5} severe or difficult to treat


1. CDC. COPD (accessed 29 Nov 2022). 2. CDC. Asthma (accessed 29 Nov 2022). 3. May S & Li J. Allergy Asthma Proc. 2015. 4. Yoo J, et al. Aust J Gen Pract. 2019. 5. Bednarek M, et al. Thorax. 2008

Remote Patient Monitoring (RPM) Solution

Shown to Improve Outcomes in a Variety of Chronic Disease States including Asthma^{6,7} and COPD⁸

.....But it's not just a Device

- + RPM qualifies for CMS CPT code reimbursement.
 - All **patients' services** are reimbursable by payors
- + Reimbursement rewards/encourage providers
- + RPM market growth CAGR of **20%+** to **US\$85Bn** by 2026⁹. US to double by 2028¹⁰.



RPM: What Customers want

For Patients



- **Live their lives**
- Easy-to-use medical devices with automatic feedback
- Ongoing relationship with clinical services staff (a friendly consistent voice)
- Peace of mind: Clinical service staff & providers together know what is happening, everyday

For Providers




- **Remain a Doctor or Hospital**
- Easy-to-use outsource model.
- No new investment in people, \$\$\$ or systems.
- Reward for providing valuable service. Reimbursement.

For Payers



- **Remain a Payer.**
- Reduce costly tertiary/hospital care delivery
- No new investments to support program delivery.
- Differentiation. Improved Star ratings and rank status versus peers



ASX: RSH
OTCQB: RSHUF



Access Acquisition

Anchoring the broader US RPM strategy

Marjan Mikel (CEO)

July 2023

Access: Successful RPM is More than a Device:

EASY

Patient takes recording
with wheezo®
Data is transferred
immediately



INFORMATION

Treating physicians
alerted by exception
and can review
patient progress at
any time



CARING HUMANS

Clinical staff review
patient data and
escalate to treating
physicians

*Today: Respi works
through partners like
ACCESS*

Respiri Highly Differentiated

wheezo® breath sensor

IP-Protected, FDA Cleared & Reimbursed



Easy for patients

56% of patients used wheezo® on average
at least once a day for the duration of the
program.¹¹

Meaningful for doctors

2 in 3 Doctors¹² pick wheeze in their top 3
physiological parameters for RPM

The wheezo® algorithm detects wheeze as well as
a respiratory specialist¹³

Scalable

Secure Cloud Storage and Integrates seamlessly into
existing health systems & partner infrastructure

11. n=22, Data on file (preliminary data)
12. n=78, Data on file, Jan 2022
13. Data on File

Access:

The Problem is more than Respiratory.

+ More than 60% of US citizens aged >55 live with two or more chronic conditions¹⁴

+ Less than 4% of providers have billed for RPM¹⁵


~50m Americans (COPD/Asthma)¹⁻³

~17%^{4,5} severe or difficult to treat



~150m Americans¹⁴ (chronic disease)

Accounts for 4.1 trillion in annual healthcare costs¹⁵



Expand to service RPM demand for a broader set of high-risk disease types (e.g., cardiovascular, diabetes and obesity)

1. CDC. COPD (accessed 29 Nov 2022). 2. CDC. Asthma (accessed 29 Nov 2022). 3. May S & Li J. Allergy Asthma Proc. 2015. 4. Yoo J, et al. Aust J Gen Pract. 2019. 5. Bednarek M, et al. Thorax. 2008

14. <https://www.rand.org/blog/rand-review/2017/07/chronic-conditions-in-america-price-and-prevalence.html>

15. <https://ncoa.org/article/get-the-facts-on-chronic-disease-self-management>

Customers want wheezo but want more than Respiratory

wheezo® led sale with expansion into broader patient cohorts



The HCO

Arkansas Heart Hospital (AHH) is a 112-bed facility serving tens of thousands of patients. It's one of the largest private cardiovascular organisations in the US.



The challenge

AHH not achieving 30-day re-admission metrics for their co-morbid patients living with CVD* and COPD^, resulting in substantial fines. AHH sought **innovative solution**.



The opportunity

ACCESS secured AHH as a customer based on the unique clinical features of wheezo® RPM. This accounted for 39% of all patients at the facility.



The solution

wheezo® led RPM program to reduce re-admission for patients with COPD^
Additional patients with CVD* disease to be RPM onboarded utilising another medical device

This moved the potential from 39% of AHH patients to almost all patients.

Respiri's **Access** acquisition is the commercial prescription



An end-to-end RPM solution

Meet **known demand for RPM across all high-risk disease types**, not just respiratory

ACCESS RPM platform is device agnostic with wheezo® as differentiating device

Turnkey solution given the existing sales and marketing partnership with ACCESS.

Critical systems **integration with ACCESS's telehealth RPM platform is already complete.**



Growing revenue and margins

Improved margins from US\$10-\$20 per patient for wheezo® device sales to \$70-\$100 per patient.

Backed by reimbursement eligibility across all RPM services.

Respiri can achieve cash flow positivity with 9,000 active RPM patients down from 30,000 wheezo® patients.



Scalable infrastructure

Provides clinical staff and services with best-practice RPM program compliance **proven to increase reimbursement claims.**

Profitable expansion potential with each team member servicing RPM for 250 patients, generating US\$240,000 p.a revenue vs \$70,000 staff cost.

The benefits

Expands total addressable market from 50m patients to 150m

Provides 7-10x growth in monthly recurring revenue per patient

Reimbursements-backed business model with profitable scalability

Accelerates monthly breakeven to H2 CY2024.

Access Full Suite RPM solution continues to appeal

New Business Opportunities/Deals

Recent Contracts:


- + **VDO Cardiology** 300 patients. ~**US\$310K** Revenues
- + **Angelic Health** 150 patients. ~**US\$150K** Revenues
- + **MLC** RTM in Sleep Apnea 150 patients . ~**US\$150K** Revenues

Advanced Discussions

- + 2 insurers.
 - initial patient contract 4,500 ~**US\$2.2M**
 - line of sight to 40,000+ in 12 months. ~**US\$20M**
- + 3 Accountable Care Organisation Contracts
 - initial patient contracts 2,000 ~**US\$1M**
 - clear line of sight to 30,000 patients ~**US\$14M**



Multiple unconflicted partnerships needed in a Fragmented RPM Market




Access Data Adding to AI strategy

AI methodologies are core to the Respi formula (wheezo algorithm)

Respi AI Today:

- + AI inherent in Respi **algorithm IP**
- + AI used to augment product development; the business has seen an **uplift of >50% in technology output**
- + AI used to analyse large customer patient data sets to **identify the most vulnerable and costly patients** (on behalf of key customers)
- + Via the acquisition, Respi now **working with large, complex data sets** (patients with multiple chronic diseases)

Future: Evolving AI strategy will allow Respi to optimise programs & deliver greater value to stakeholders



The Respiri Difference: Near-term growth drivers

Poised to accelerate a significant US opportunity



Enhanced economics

- Significant revenue upside supported by **reimbursements**
- Access Significantly improved margins driving **7-10x growth**
- CY2024 path to break even (approx. 9K patients)
- **Near Term ~US\$5M in new contracts**



Growth opportunities

- Multiplies total addressable market and expands into RPM for new disease types
- Infrastructure in place to support scaling of offering across thousands of new customers
- Existing customer base and contract pipeline



Proven delivery team

- Board and Exec team with track-record of commercializing RPM offerings
- Experienced ACCESS executive and clinical team
- Led by Respiri's US head of operations

Key H2, 2023 Milestone Deliverables

- **New Access commercial contracts**
- **First FiMed wheezo RPM contract**
- **Continued revenue growth.**
- **Wearable device clinical study 1st patient enrolment**
- **Birmingham wheezo lung function study results**



The Difference For Commercial Success

Becoming a leading end-to-end RPM provider

Respiri today

An eHealth SAAS company supporting respiratory health management

- Growing adoption of wheezo® device and respiratory RPM service
- Distribution partners that leverage wheezo®'s advantages yet deliver broader RPM services



Access Future state

A diversified RPM provider with an integrated solution

- Combining in-house IP with other medical device RPM services
- Superior clinical services capability to meet customer and patient demand
- Proven program delivery with a best-in-class experience
- Platform to increase revenue, margins and customer acquisition

Underpinned by the unique and leading market profile of wheezo®, which will continue to provide an entry point to grow scope of RPM contracts with healthcare providers

Disclaimer statement

This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company.

Speculative nature of investment: An investment in Shares of the Company should be considered very speculative. No assurance as to future profitability or dividends can be given as they are dependent on successful product development, future earnings and the working capital requirements of the Company. The Board does not envisage in the immediate future that the Company will generate sufficient revenue to be profitable or be in a position to declare any dividends. The financial prospects of the Company are dependent on a number of factors, including successfully completing further product development, gaining regulatory approvals, the degree of market acceptance or take-up of its products and the amount of competition encountered from competitive or alternative products developed by third parties. There is no guarantee that the Company's development work will result in commercial sales or that the Company will achieve material market penetration.

Competition: The medical device and digital health industries are highly competitive and include companies with significantly greater financial, technical, human, research and development, and marketing resources than the Company. There are companies that compete with the Company's efforts to develop, and commercialise its products.

Reliance on Key Personnel & Service Providers: The Company currently employs a small number of key personnel, and the Company's future depends on retaining and attracting suitably qualified personnel. There is no guarantee that the Company will be able to attract and retain suitably qualified personnel, and a failure to do so could materially and adversely affect the business, operating results and financial prospects. The Company operates a significant amount of its key activities through a series of contractual relationships with independent contractors and suppliers. All of the Company's contracts carry a risk that the third parties do not adequately or fully comply with its or their respective contractual rights and obligations. Such failure can lead to termination and/or significant damage to the Company's product development efforts.

Sufficiency of Funding: The Company has limited financial resources and will need to raise additional funds from time to time to finance the complete development and commercialisation of its products. The Company's ability to raise additional funds will be subject to, among other things, factors beyond the control of the Company and its Directors, including cyclical factors affecting the economy and share markets generally. The Directors can give no assurance that future funds can be raised by the Company on favourable terms, if at all.

Technological Development: Medical device research and product development involve scientific, software and engineering uncertainty and long lead times. There is no certainty as to whether any particular event or project will occur within a set period or by a certain date.

Regulatory Risk: Medical device products are regulated by government agencies and must be approved prior to commercial sales. Complex government health regulations increase uncertainty and are subject to change at any time. As such the risk exists that the Company's new or existing products may not satisfy the stringent requirements for approval, the approval process may take longer than expected or previous approvals may be altered or revoked. This may adversely affect the Company's competitive position and the financial value of the medical devices to the Company.

Product Liability & Manufacturing Risks: As with all new products, even after the granting of regulatory approval, there is no assurance that unforeseen adverse events or manufacturing defects will not arise. Adverse events could expose the Company to product liability claims or litigation, resulting in the removal of the regulatory approval for the relevant products and/or monetary damages being awarded against the Company. In such event, the Company's liability may exceed the Company's insurance coverage. If any products do not meet suitability or quality assurance standards, this may result in increased costs and may delay sales.

Trade Secrets & Patents: The Company relies on its trade secrets and patent rights. It cannot be certain that others will not independently develop the same or similar technologies on their own or gain access to trade secrets or disclose such technology, or that the Company will be able to meaningfully protect its trade secrets and unpatented know-how and keep them secret. The Company's existing intellectual property rights include its copyright in source code used in its digital health technologies, its know-how in the development of digital health products and data arising from the use of its digital health products. There is no guarantee that the Company's intellectual property comprises all of the rights that the Company may require to freely commercialise its product candidates. The granting of a patent in one country does not mean the patent application will be granted in other countries and competitors may at any time challenge granted patents and a court may find that the granted patent is invalid or unenforceable or revoked.

Stock Market Volatility: The performance of the share market may affect the Company and the price at which its shares trade on a share market. The share market has in the past and may in the future be affected by a number of matters.

Customer contracts: The Company's ability to distribute and ultimately sell its products is subject to a small number of commercial agreements. There is a risk that these contracts could be breached, not complied with according to their terms, terminated or substantially modified in a way which adversely affects the ability for the Company to sell its products or creates a significant liability for the Company.

Respiri Limited Risk Factors